Table 2 Therapeutic characteristics of study population (Mean ± SD)
From: Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran
Age of start of transfusion | 15.4 ± 18.8(month) |
Age of start of desferrioxamine | 5.1 ± 3.1(yr) |
Pretranfusion hemoglobin in last year | 9.6 ± 2.3(g/dl) |
Ferritin | 1441 ± 1111.3(μg/l) |